Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 274-282 , June 2005

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer

  • David Dodwell

      Affiliations

    • Cookridge Hospital, Leeds, Yorkshire LS16 6QB, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 (0) 1133 924 237; fax: +44 (0) 1133 924 052
    • ,
  • Ignace Vergote

      Affiliations

    • Department of Obstetrics and Gynaecology, University Hospital Leuven, Gasthuisberg, Herestraat 49, BE-3000 Leuven, Belgium

References 

  1. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001;28:291–304
  2. Robertson JF, Nicholson RI, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61:6739–6746
  3. Steger G, Bartsch R, Wenzel C, et al. Fulvestrant Faslodex® in metastatic breast cancer. Breast Cancer Res Treat. 2003;82(Suppl 1):S104;[Abstract 437]
  4. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–3403
  5. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386–3395
  6. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229–238
  7. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001;19:3357–3366
  8. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998;83:1142–1152
  9. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453–461
  10. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18:1399–1411
  11. Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer. 2003;39:2318–2327
  12. Pippen J, Osborne CK, Howell A, Robertson JFR. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials. Breast Cancer Res Treat. 2003;82(Suppl 1):S101;abs 426
  13. Vergote I, Robertson JFR, Kleeberg U, et al. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003;79:207–211
  14. Messori A, Cattel F, Trippoli S, Vaiani M. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anticancer Drugs. 2000;11:701–706
  15. Carlini P, Bria E, Giannarelli D, et al. New aromatase inhibitors (AIs) as 2nd-line endocrine therapy (ET) in metastatic breast cancer (MBC): a comprehensive review of 5832 women from 14 phase III trials. J Clin Oncol. 2004;22:
  16. Stenbygaard LE, Herrstedt J, Thomsen JF, et al. Toremifene and tamoxifen in advanced breast cancer – a double-blind cross-over trial. Breast Cancer Res Treat. 1993;25:57–63
  17. Vogel CL, Shemano I, Schoenfelder J, et al. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol. 1993;11:345–350
  18. The ATAC Trialists’ Group . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  19. Chan CM, Martin LA, Johnston SR, et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol. 2002;81:333–341
  20. Jeng MH, Shupnik MA, Bender TP, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology. 1998;139:4164–4174
  21. Martin LA, Farmer I, Johnston SR, et al. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003;278:30458–30468
  22. Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology. 2000;141:396–405
  23. Perey L, Paridaens R, Nolé F, et al. Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat. 2004;88(Suppl 1):S236;[Abstract 6048]
  24. Petruzelka L, Zimovjanova M. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – results from an expanded access programme. Eur J Cancer. 2004;(Suppl 2):132;[Abstract 264]
  25. Franco S, Perez A, Tan-Chiu E, et al. Fulvestrant Faslodex® demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience. Breast Cancer Res Treat. 2003;82(Suppl 1):S105;[Abstract 439]

PII: S0305-7372(05)00050-2

doi: 10.1016/j.ctrv.2005.03.009

Cancer Treatment Reviews
Volume 31, Issue 4 , Pages 274-282 , June 2005

Article Tools

* Image Usage & Resolution